Inhibikase Therapeutics, Inc.
NASDAQ:IKTBiotechnology
+$0.06 today
- Market cap
- $193.57M
- Beta
- 0.97
- P/E (TTM)
- -3.4
- EPS (TTM)
- -$0.52
Volume 0.43M
Average 1.03M
IKT Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Inhibikase Therapeutics, Inc.NASDAQ: IKT
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income grows, but more slowly than its trailing trend
Q1 FY2026 net income of $16.38M (cash outflow) rose 19.8% year over year, behind the +39.4% change in trailing-twelve-month net income. Sequentially, it rose 28.6% from the prior quarter. Over 3 fiscal years it compounded at +38.8% a year.
Context
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 7 analysts of -$41.01M (-15.0%) for the fiscal year ending Dec 2026, a slowdown from the +75.4% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$16.38M+28.6% QoQ
- Last fiscal yearDec 2025
- -$48.26M+75.4% YoY
- LTMMar 2026
- -$50.96M+39.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +19.8% | +89.3% | +69.5 pp |
| 1 year | +75.4% | -15.0% | -90.4 pp |
| 3-year CAGR | +38.8% | -4.0% | -42.8 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (48.26M) USD
- Year-over-year change
- -75.4%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (48.26M) | -75.4% |
| FY2024 | 2024-12-31 | (27.52M) | -44.6% |
| FY2023 | 2023-12-31 | (19.03M) | -5.4% |
| FY2022 | 2022-12-31 | (18.05M) | -22.1% |
| FY2021 | 2021-12-31 | (14.79M) | — |
Net Income vs competitors
How IKT compares with its peers on the latest reported figures
- IKT's LTM Mar 2026 net income of $50.96M is the 3rd largest of the 8 companies compared; the peer median is $12.38M.
- Its year-over-year change of +39.4% is the 4th highest of 7, against a peer median of +37.7%.
- Over three fiscal years its annual growth of +38.8% compares with a peer median of +19.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $342.56M | +319.3% | +88.7% | 4571.1% | |
| LTM Mar 2026 | $62.51M | +132.2% | +0.2% | 50.5% | |
| LTM Mar 2026 | $50.96M | +39.4% | +38.8% | — | |
| LTM Mar 2026 | $21.76M | +31.3% | +35.2% | — | |
| LTM Mar 2026 | $19.58M | -41.2% | +3.2% | — | |
| LTM Mar 2026 | $12.38M | +22.7% | -4.3% | — | |
EXOZeXoZymes, Inc. | LTM Mar 2026 | $9.67M | +44.2% | +87.2% | — |
TTRXTurn Therapeutics Inc. | LTM Mar 2026 | $3.84M | — | — | — |
| Peer median (excluding IKT) | $12.38M | +37.7% | +19.2% | 2310.8% | |
Competitors are the stored peer set for IKT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (14.79M) | (18.05M) | (19.03M) | (27.52M) | (48.26M) |
| Depreciation & Amortization | 0 | 6.72K | 177.4K | 26.27K | 60.5K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.53M | 458.15K | 500.15K | 8.14M | 15.31M |
| Change in Working Capital | (1.76M) | 171.18K | 234.76K | 204.93K | 55.93K |
| Accounts Receivables | (110.14K) | 70.26K | 39.88K | 0 | 0 |
| Inventory | 1.3M | 0 | 0 | 0 | 0 |
| Accounts Payables | (630.9K) | 61.4K | (504.41K) | 271.78K | 146.83K |
| Other Working Capital | (2.33M) | 39.53K | 699.28K | (66.85K) | (90.9K) |
| Other Non-Cash Items | 721.63K | 67K | 31.54K | 0 | 5.05M |
| Operating Cash Flow | (14.3M) | (17.35M) | (18.09M) | (19.15M) | (27.79M) |
| Capital Expenditures | 1 | (243.26K) | (14.24K) | 0 | (13.4K) |
| Acquisitions (Net) | 0 | 243.26K | 0 | 0 | 0 |
| Purchases of Investments | 0 | (20.73M) | (29.43M) | (60.46M) | (39.09M) |
| Sales of Investments | 0 | 4.96M | 41.1M | 23.45M | 41.6M |
| Other Investing Activities | 0 | (243.26K) | 0 | 0 | 0 |
| Investing Cash Flow | 0 | (16.01M) | 11.66M | (37M) | 2.05M |
| Debt Repayment | (42.53K) | (248.91K) | 0 | 0 | 0 |
| Common Stock Issued | 41.14M | 44.14K | 8.54M | 103.48M | 108.46M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 848 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 41.09M | (204.77K) | 8.41M | 103.48M | 108.46M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 26.8M | (33.56M) | 1.98M | 47.33M | 82.73M |
| Free Cash Flow | (14.3M) | (17.59M) | (18.1M) | (19.15M) | (27.79M) |
Inhibikase Therapeutics, Inc.
NASDAQ:IKT
Intrinsic Alpha fair value
Locked
Current Price
$1.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.